- Home
- FNLC vs TARA Comparison
FNLC vs TARA Comparison
Compare FNLC & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | TARA |
|---|---|---|
| Founded | 1864 | N/A |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 268.5M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FNLC | TARA |
|---|---|---|
| Price | $29.50 | $6.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 15.8K | ★ 790.4K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 39.22 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.11 | $2.77 |
| 52 Week High | $30.33 | $7.82 |
Technical Indicators
Market Signals| Indicator | FNLC | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 58.79 |
| Support Level | $28.88 | $6.25 |
| Resistance Level | $29.71 | $6.82 |
| Average True Range (ATR) | 0.72 | 0.39 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 64.29 | 42.27 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).